Evidence map›Paper›PMID 38792217›Full record

ArticleMolecules (Basel, Switzerland)2024

Pre-Steady-State and Steady-State Kinetic Analysis of Butyrylcholinesterase-Catalyzed Hydrolysis of Mirabegron, an Arylacylamide Drug.

Zukhra Shaihutdinova, Patrick Masson

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zukhra ShaihutdinovaLaboratory of Biochemical Neuropharmacology, Kazan Federal University, Kremlevskaya St. 18, 420008 Kazan, Russia.ORCID 0009-0008-5713-4137
Patrick MassonLaboratory of Biochemical Neuropharmacology, Kazan Federal University, Kremlevskaya St. 18, 420008 Kazan, Russia.ORCID 0000-0002-7837-3662

Funding

Kazan Federal University Priority 2030
6 · The paper itself

Abstract

The β-adrenergic drug Mirabegron, a drug initially used for the treatment of an overactive bladder, has new potential indications and is hydrolyzed by butyrylcholinesterase (BChE). This compound is one of the only arylacylamide substrates to be catabolized by BChE. A steady-state kinetic analysis at 25 °C and pH 7.0 showed that the enzyme behavior is Michaelian with this substrate and displays a long pre-steady-state phase characterized by a burst. The induction time,

Indexed as

AcetanilidesButyrylcholinesteraseThiazolesCatalysisHumansHydrolysisKineticsAcetanilidesButyrylcholinesterasemirabegronThiazolesarylacylamideburstbutyrylcholinesterasedrug metabolismhysteretic enzymemirabegron

Identifiers

PMID38792217
PMCPMC11124411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.